Mode
Text Size
Log in / Sign up

Urolithin A supplementation shows directionally favorable but statistically inconclusive improvements in 6-minute walk testTrial shows Urolithin A may improve walking distance

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that Urolithin A shows a directionally favorable but statistically inconclusive effect on 6-minute walk test distance.

This meta-analysis evaluated the effects of oral Urolithin A supplementation (500 mg and 1,000 mg) compared to placebo on physical performance and mitochondrial biomarkers in humans. The analysis included a total sample size of 236 participants across multiple studies.

The primary outcome, the 6-minute walk test (6MWT), showed a pooled mean difference of +17.03 m. However, this result was statistically inconclusive with a 95% CI of -5.33 to 39.40 m and a p-value of 0.135. Secondary outcomes including muscle strength, endurance, aerobic capacity, and various biochemical or mitochondrial biomarkers were reported but not quantitatively pooled due to heterogeneity.

The authors noted several limitations, including small and short-term trial designs, clinically heterogeneous populations, and low GRADE certainty for the 6MWT outcome. Because results regarding strength and mitochondrial markers are exploratory and evidence is limited by study design, there is currently insufficient evidence to make firm clinical recommendations for Urolithin A.

Walking even a short distance can be a challenge for many people. Researchers looked at how taking a supplement called Urolithin A affects physical performance, specifically focusing on how far people could walk in six minutes. This look into the data helps us understand if this compound has potential for those struggling with mobility.

The study included 236 people who took either 500 mg or 1,000 mg of Urolithin A daily, while others took a placebo. Those taking the supplement showed a trend toward walking further than those who did not. However, because the results were not statistically certain and the trials were small and short-term, we cannot say for sure if it works yet.

Other factors like muscle strength and endurance were also looked at, but these findings are still in early stages. Because the study groups were very different from one another, the evidence is currently considered low certainty. It is too early to make firm medical recommendations based on this data alone.

What this means for you:
Urolithin A shows a positive trend for walking distance, but more large-scale studies are needed.

Common questions

Does Urolithin A help with walking distance?

The study showed a positive trend where participants taking Urolithin A walked about 17 meters further in a six-minute test. However, the results were not statistically certain, meaning more research is needed to confirm if this change is consistent across different groups of people.

What doses of Urolithin A were tested?

The study looked at two different daily doses: 500 mg and 1,000 mg. While these doses showed a positive direction for walking distance, the small size and short length of the trials mean we cannot make firm clinical recommendations yet.

Does Urolithin A improve muscle strength or endurance?

Researchers looked at muscle strength, endurance, and aerobic capacity as secondary outcomes. Because these results were exploratory and the study groups were very different from each other, there is not enough evidence yet to confirm if it improves these specific areas.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Urolithin A (UA), a gut microbiota–derived metabolite, has been proposed to improve skeletal muscle function, but evidence from randomized controlled trials has not been systematically summarized. This systematic review and meta-analysis aimed to evaluate the effects of UA supplementation on muscle performance as well as biochemical and mitochondrial biomarkers in humans. Randomized controlled trials published up to December 2025 were identified through systematic searches of four electronic databases: PubMed, Embase, Web of Science, and Scopus. Trials comparing oral UA supplementation with placebo and reporting muscle-related outcomes were included. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, and the certainty of evidence for the primary quantitatively synthesized outcome was rated using the GRADE approach. Quantitative meta-analysis was feasible only for the 6-min walk test (6MWT); remaining outcomes were synthesized narratively. For multi-arm trials with a shared comparator, intervention arms were combined into a single group following Cochrane Handbook guidance to avoid unit-of-analysis errors. Pooled mean differences with 95% confidence intervals were calculated using inverse-variance weighting, with both fixed-effect and random-effects sensitivity analyses. Five randomized controlled trials (n = 236) were included. Quantitative synthesis was feasible only for the 6MWT (k = 2). After combining the 500 mg and 1,000 mg Urolithin A arms of Singh et al. (5) against the shared placebo group, the pooled mean difference was +17.03 m (95% CI −5.33 to 39.40 m; p = 0.135; I2 = 0%); a sensitivity analysis using placebo-group splitting yielded a comparable estimate (+18.80 m; 95% CI −3.24 to 40.85 m; p = 0.095). The certainty of evidence for the 6MWT outcome was rated as low (GRADE). Non-6MWT outcomes — muscle strength, endurance, aerobic capacity, and biochemical or mitochondrial biomarkers — were heterogeneous across populations, doses, and assessment modalities, were not quantitatively pooled, and are reported as exploratory signals rather than reproducible effects. The currently available randomized human evidence is limited to five small, short-term trials in clinically heterogeneous populations. Quantitative pooling was feasible for a single outcome (6MWT) based on two trials and showed a directionally favorable but statistically inconclusive effect with low GRADE certainty. Narrative findings on strength, endurance, and mitochondrial-related biomarkers are exploratory and hypothesis-generating, not reproducible evidence of efficacy. Larger, longer, and methodologically standardized trials in better-defined populations are required before firm clinical recommendations can be made. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251270987, identifier: PROSPERO 2025 CRD420251270987.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.